胶质母细胞瘤放射病理组学图谱识别与非增强肿瘤浸润表型相关的贝伐珠单抗治疗反应
本研究利用T1、T1C、FLAIR和ADC图像为79例原发性GBM或高级别IDH1突变星形细胞瘤患者生成放射病理组学图谱,定义非增强肿瘤前沿的四种表型。Kaplan-Meier分析显示,边界清晰型患者生存优于其他表型;仅少细胞型或混合型前沿患者从贝伐珠单抗治疗中获得显著生存获益,且少细胞型体积在治疗期间平均每日减少50.52 mm³。
要点
- 边界清晰型前沿患者生存优于富细胞型、少细胞型和混合型前沿患者。
- 仅少细胞型或混合型前沿患者从贝伐珠单抗治疗中获得显著生存获益。
- 少细胞型体积在贝伐珠单抗治疗期间平均每日减少50.52 mm³。
核心结论
- 放射病理组学图谱识别的少细胞型肿瘤前沿患者接受贝伐珠单抗治疗时显示改善的治疗疗效,治疗过程中少细胞型体积减少可能提示治疗反应。
研究设计与样本
- 本研究纳入79例治疗前原发性胶质母细胞瘤或高级别IDH1突变星形细胞瘤患者,使用T1、T1C、FLAIR和ADC图像生成肿瘤特征的放射病理组学图谱,并对非增强肿瘤前沿进行新型表型分型(富细胞型、少细胞型、混合型或边界清晰型)。
- 采用Kaplan-Meier分析评估表型间生存差异和贝伐珠单抗疗效差异;对26例患者子集在贝伐珠单抗治疗过程中纵向生成表型分区分割,并使用混合效应模型检测纵向变化。
主要发现
- 边界清晰型患者较富细胞型前沿患者生存显著/趋势增加(HR=2.0,p=0.05),较少细胞型前沿患者生存显著增加(HR=2.02,p=0.03),较混合型前沿肿瘤患者生存趋势增加(HR=1.75,p=0.09)。
- 仅少细胞型或混合型前沿患者从贝伐珠单抗治疗中获得显著生存获益(HR=2.35,p=0.02;HR=2.45,p=0.03)。
- 少细胞型体积在贝伐珠单抗治疗期间平均每日减少50.52 mm³(p=0.002)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autopsy-based radio-pathomic maps of glioma pathology have shown substantial promise inidentifying areas of non-enhancing tumor presence, which may be able to differentiate subsets of patients that respond favorably to treatments such as bevacizumab that have shown mixed efficacy evidence. We tested the hypthesis that phenotypes of non-enhancing tumor fronts can distinguish between glioblastoma patients that will respond favorably to bevacizumab and will visually capture treatment response. METHODS: T1, T1C, FLAIR, and ADC images were used to generate radio-pathomic maps of tumor characteristics for 79 pre-treatment patients with a primary GBM or high-grade IDH1-mutant astrocytoma for this study. Novel phenotyping (hypercellular, hypocellular, hybrid, or well-circumscribed front) of the non-enhancing tumor front was performed on each case. Kaplan Meier analyses were then used to assess differences in survival and bevacizumab efficacy between phenotypes. Phenotype compartment segmentations generated longitudinally for a subset of 26 patients over the course of bevacizumab treatment, where a mixed effect model was used to detect longitudinal changes. RESULTS: Well-Circumscribed patients showed significant/trending increases in survival compared to Hypercellular Front (HR = 2.0, p = 0.05), Hypocellular Front (HR = 2.02, p = 0.03), and Hybrid Front tumors (HR = 1.75, p = 0.09). Only patients with hypocellular or hybrid fronts showed significant survival benefits from bevacizumab treatment (HR = 2.35, p = 0.02; and HR = 2.45, p = 0.03, respectively). Hypocellular volumes decreased by an average 50.52 mm3 per day of bevacizumab treatment (p = 0.002). CONCLUSION: Patients with a hypocellular tumor front identified by radio-pathomic maps showed improved treatment efficacy when treated with bevacizumab, and reducing hypocellular volumes over the course of treatment may indicate treatment response.
引用
- Bobholz SA, Hoefs A, Hamburger J, et al. Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response. J Neurooncol. 2024. PMID: 38372901. doi:10.1007/s11060-024-04593-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。